Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone

Bibliography

• Kim JB, Stein R, O'Hare MJ. Tumor-stromal interactions in breast cancer: the role of stroma in tumorigenesis. Tumor Biol 2005;26:173-85
   PubMed Web of Science ®Google Scholar
• Erickson AC, Barcellos-Hoff MH. The not-so innocent bystander: the microenvironment as a therapeutic target in cancer. Expert Opin Ther Targets 2003;7:71-88
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, Depinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887-907
   PubMed Web of Science ®Google Scholar
• Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007;8:279-87
   PubMed Web of Science ®Google Scholar
• Mahadevan D, von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97
   PubMed Web of Science ®Google Scholar
• Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007;101:805-15
   PubMed Web of Science ®Google Scholar
• Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 2007;101:830-9
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18
   PubMed Web of Science ®Google Scholar
• Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 2007;117:50-59
   PubMed Web of Science ®Google Scholar
• Micke P, Ostman A. Tumor-stroma interaction: cancer-associated fibroblasts as novel targets in anticancer therapy? Lung Cancer 2004;45(Suppl 2):S163-S175
   PubMed Web of Science ®Google Scholar
• Micke P, Ostman A. Exploring the tumor environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 2005;9:1217-33
   PubMed Web of Science ®Google Scholar
• Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002;35:S79-S85
   PubMed Web of Science ®Google Scholar
• Okita K, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002;62:24-28
   PubMed Web of Science ®Google Scholar
• Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225-37
   PubMed Web of Science ®Google Scholar
• Menke A, Adler G. TGFβ-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer 2002;31:41-46
   PubMedGoogle Scholar
• Go VL, Gukovskaya A, Pandol SJ. Alcohol and pancreatic cancer. Alcohol 2005;35:205-11
   PubMed Web of Science ®Google Scholar
• Maisonneuve P, Lowenfels AB. Chronic pancreatitis and pancreatic cancer. Dig Dis 2002;20:32-37
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Radisky DC. Putting tumors in context. Nat Rev Cancer 2001;1:46-54
   PubMed Web of Science ®Google Scholar
• Hasebe T, Mukai K, Tsuda H, Ochiai A. New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int 2000;50:263-72
   PubMed Web of Science ®Google Scholar
• Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998;49:195-208
   PubMed Web of Science ®Google Scholar
• Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc 2004;37:3-15
   PubMedGoogle Scholar
• Walker GA, Guerrero IA, Leinwand LA. Myofibroblasts: molecular crossdressers. Curr Top Dev Biol 2001;51:91-107
   PubMed Web of Science ®Google Scholar
• Hast J, Schiffer IB, Neugebauer B, et al. Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice. Anticancer Res 2002;22:677-88
   PubMed Web of Science ®Google Scholar
• Qi W, Chen X, Poronnik P, Pollock CA. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol 2006;38:1-5
   PubMed Web of Science ®Google Scholar
• Ogawa M, laRue AC, Drake CJ. Hematopoietic origin of fibroblasts/myofibroblasts: its pathophysiologic implications. Blood 2006;108:2893-6
   PubMed Web of Science ®Google Scholar
• Willis BC, DuBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006;3:377-82
   PubMedGoogle Scholar
• Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L525-L534
   PubMed Web of Science ®Google Scholar
• Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tiss Organs 2007;185:222-31
   PubMed Web of Science ®Google Scholar
• Magness ST, Battaler R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:1151-9
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006;5:1640-6
   PubMed Web of Science ®Google Scholar
• Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007;257:143-79
   PubMed Web of Science ®Google Scholar
• Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastro Hepatol 1999;14:618-33
   PubMed Web of Science ®Google Scholar
• Yashiro M, Ikeda K, Tendo M, et al. Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells. Breast Cancer Res Treat 2005;90:307-13
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48
   PubMed Web of Science ®Google Scholar
• Singh H, Dang TD, Ayala GE, Rowley DR. Transforming growth factor-β1 induced myofibroblasts regulate LNCaP cell death. J Urol 2004;172:2421-5
   PubMed Web of Science ®Google Scholar
• Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83
   PubMed Web of Science ®Google Scholar
• Adegboyega PA, Mifflin RC, DiMari JF, et al. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med 2002;126:829-36
   PubMed Web of Science ®Google Scholar
• Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001;158:1451-63
   PubMed Web of Science ®Google Scholar
• Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 2003;5:130-5
   PubMed Web of Science ®Google Scholar
• Mikula M, Proell V, Fischer AN, Mikulits W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-β dependent fashion. J Cell Physiol 2006;209:560-7
   PubMed Web of Science ®Google Scholar
• Theret N, Musso O, Turlin B, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001;34:82-88
   PubMed Web of Science ®Google Scholar
• Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005;128:907-21
   PubMed Web of Science ®Google Scholar
• Erkan M, Kleeff J, Gorbachevski A, et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007;132:1447-64
   PubMed Web of Science ®Google Scholar
• Schneider G, Siveke JT, Eckel F, Schmidt RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005;128:1606-25
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Mauviel A. Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211-15
   PubMed Web of Science ®Google Scholar
• Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007;98:1512-20
   PubMed Web of Science ®Google Scholar
• de Wever O, Westbroek W, Verloes A, et al. Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-β or wounding. J Cell Sci 2004;117:4691-703
   PubMed Web of Science ®Google Scholar
• Flanders KC, Sullivan CD, Fujii M, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002;160:1057-68
   PubMed Web of Science ®Google Scholar
• Zhao J, Shi J, Wang YL, et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585-L593
   PubMed Web of Science ®Google Scholar
• Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006;17:19-27
   PubMed Web of Science ®Google Scholar
• Takaya Y, Tasaka H, Chiba T, et al. New type of febrifugine analogs, bearing a quinolizidine moiety, show potent antimalarial activity against plasmodium malaria parasite. J Med Chem 1999;42:3163-6
   PubMed Web of Science ®Google Scholar
• Pines M, Vlodavsky I, Nagler A. Halofuginone: from veterinary use to human therapy. Drug Develop Res 2000;50:371-8
   Web of Science ®Google Scholar
• Pines M, Nagler A. Halofuginone – a novel antifibrotic therapy. Drugs Fut 1996;21:569-99
   Google Scholar
• Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998;30:445-50
   PubMedGoogle Scholar
• Halevy O, Nagler A, Levi-Schaffer F, et al. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996;52:1057-63
   PubMed Web of Science ®Google Scholar
• Pines M, Knopov V, Genina O, et al. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 1997;27:391-8
   PubMed Web of Science ®Google Scholar
• Nagler A, Rivkind AI, Raphael J, et al. Halofuginone – an inhibitor of collagen type I synthesis – prevents postoperation abdominal adhesions formation. Ann Surg 1998;227:575-82
   PubMed Web of Science ®Google Scholar
• Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft versus host disease and scleroderma. Biol Bl Marrow Transplant 2003;9:417-25
   PubMed Web of Science ®Google Scholar
• McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-70
   PubMed Web of Science ®Google Scholar
• Turgeman T, Hagai Y, Huebner K, et al. Inhibition of Smad3 phosphorylation by halofuginone prevents muscle fibrosis and improves muscle performance in the mdx mouse model of Duchenne muscular dystrophy. 2007;submitted
   Google Scholar
• Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-β signaling. Cell Tiss Res 2007;328:153-66
   PubMed Web of Science ®Google Scholar
• Xavier S, Piek E, Fujii M, et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-β signaling by halofuginone. J Biol Chem 2004;279:15167-76
   PubMed Web of Science ®Google Scholar
• Yee KO, Connolly CM, Pines M, Lawler J. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 2006;5:218-24
   PubMed Web of Science ®Google Scholar
• Nagler A, Genina O, Lavelini, et al. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am J Obstet Gynecol 1999;180:558-63
   PubMed Web of Science ®Google Scholar
• Nagler A, Gofrit O, Ohana M, et al. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 2000;164:1776-8
   PubMed Web of Science ®Google Scholar
• Bruck R, Genin O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-86
   Google Scholar
• Nagler A, Irman, Feferman R, et al. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996;154:1082-6
   PubMed Web of Science ®Google Scholar
• Levi-Schaffer F, Nagler A, Slavin S, et al. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 1996;106:84-88
   PubMed Web of Science ®Google Scholar
• Pines M, Domb A, Ohana M, et al. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol 2001;62:1221-7
   PubMed Web of Science ®Google Scholar
• Spira G, Mawasi N, Paizi M, et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002;37:331-9
   PubMed Web of Science ®Google Scholar
• McGaha T, Kodera T, Phelps R, et al. Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity 2002;35:277-82
   PubMed Web of Science ®Google Scholar
• Petridou S, Maltseva O, Spanakis S, Masur SK. TGF-β receptor expression and smad2 localization are cell density dependent in fibroblasts. Invest Ophthalmol Vis Sci 2000;41:89-95
   PubMed Web of Science ®Google Scholar
• Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56-66
   PubMed Web of Science ®Google Scholar
• Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-23
   PubMed Web of Science ®Google Scholar
• Preaux AM, D'Ortho MP, Braletmp, et al. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloprotease-2. Hepatology 2002;36:615-22
   PubMed Web of Science ®Google Scholar
• Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloprotease-1 is mediated via effects on matrix metalloprotease inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-76
   PubMed Web of Science ®Google Scholar
• Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999;68:1806-9
   PubMed Web of Science ®Google Scholar
• Elkin M, Reich R, Nagler A, et al. Inhibition of matrix metalloprotease-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999;5:1982-8
   PubMed Web of Science ®Google Scholar
• Nagler A, Ohana M, Leiba M, et al. Effect of halofuginone, a collagen α1(I) inhibitor, on wound healing in normal and irradiated skin: implication for hematopoietic stem cell transplantation. Acta Haematol 2007;118:77-83
   PubMed Web of Science ®Google Scholar
• Tacheau C, Michel L, Farge D, et al. Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices. Eur J Pharmacol 2007;573:65-69
   PubMed Web of Science ®Google Scholar
• Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9
   PubMed Web of Science ®Google Scholar
• Abramovitch R, Dafni H, Neeman M, et al. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1999;1:321-9
   PubMedGoogle Scholar
• Elkin M, Miao HQ, Nagler A et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000;14:2477-85
   PubMed Web of Science ®Google Scholar
• Gavish Z, Pinthus JH, Barak V, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002;51:73-83
   PubMed Web of Science ®Google Scholar
• Abramovitch R, Itzik A, Harel H, et al. Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model – an MRI study. Neoplasia 2004;6:480-9
   PubMed Web of Science ®Google Scholar
• Pinthus JH, Sheffer Y, Nagler A, et al. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol 2005;174:1527-31
   PubMed Web of Science ®Google Scholar
• Elkin M, Ariel I, Miao HQ, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999;59:4111-18
   PubMed Web of Science ®Google Scholar
• Taras D, Blanc JF, Rullier A, et al. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 2006;8:312-18
   PubMed Web of Science ®Google Scholar
• Gross DJ, Reibstein I, Weiss L, et al. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 2003;9:3788-93
   PubMed Web of Science ®Google Scholar
• Nagler A, Ohana M, Shibolet O, et al. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 2004;40:1397-403
   PubMed Web of Science ®Google Scholar
• Sheffer Y, Leon O, Pinthus JH, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther 2007;6:570-7
   PubMed Web of Science ®Google Scholar
• De Jong MJ, Dumez H, Verweij J, et al. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumors. Eur J Cancer 2006;42:1768-74
   PubMed Web of Science ®Google Scholar